| 研究課題/領域番号 |
19K08857
|
|---|
| 研究機関 | 順天堂大学 |
|---|
研究代表者 |
ハイジッヒ ベアーテ 順天堂大学, 医学(系)研究科(研究院), 特任准教授 (30372931)
|
|---|
| 研究分担者 |
服部 浩一 順天堂大学, 医学(系)研究科(研究院), 特任先任准教授 (10360116)
|
|---|
| 研究期間 (年度) |
2019-04-01 – 2022-03-31
|
| キーワード | multiple myeloma / angiogenesis / notch receptor / cancer / integrins |
|---|
| 研究実績の概要 |
The angiocrine factor Egfl7 has been implicated in various types of cancer from solid to liquid types where it serves as a prosurvival factor and a growth factor to promote angiogenesis.
Multiple myeloma is a plasma cell malignancy that causes multi-organ damage and bone lesions. Many studies demonstrated that neoangiogenesis contributes to the progression of angiogenesis.
In this project, we hypothesized that Egfl7 drives multiple myeloma progression and drug resistance. In the first year, we showed that Eglf7 is overexpressed in malignant plasma cells, and that know down of Egfl7 can slow down tumor growth.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
In the second (last) year, we could show that the treatment of multiple myeloma cells with chemotherapeutic drugs can upregulate Egfl7 in plasma cells and that anti-Egfl7 strategies given in combination with chemotherapeutic drugs can improve anti-myeloma effects both in vitro and in vivo.
The following manuscripts were published within the last fiscal year linked to this project:
|
| 今後の研究の推進方策 |
Measures to promote future research. within 800 characters.
The focus of this year will be to better understand the underlying mechanism on how Egfl7 conveys pro-survival signals on malignant myeloma and endothelial cells. Egfl7 can signal through various receptors including Notch receptors and various integrins. We are currently studying the ligand-receptor interactions responsible for the pro-survival and pro-angiogenic actions of Egfl7 in multiple myeloma.
|
| 次年度使用額が生じた理由 |
希望した物品が年度内に納品不可能となったため、次年度に発注・納品することといたしました。Distillde Water 300mL 2448円
|
